Skip to main content
XTL Biopharmaceuticals Ltd. logo

XTL Biopharmaceuticals Ltd. — Investor Relations & Filings

Ticker · XTLB ISIN · IL0010854979 LEI · 529900NDDXEAPTUTXP41 TA Manufacturing
Open in API
Filings indexed 1,223 across all filing types
Latest filing 2007-05-29 Report Publication Anno…
Country IL Israel
Listing TA XTLB

About XTL Biopharmaceuticals Ltd.

https://www.xtlbio.com

XTL Biopharmaceuticals Ltd. is a clinical-stage biopharmaceutical company focused on the acquisition and development of pharmaceutical products to address unmet clinical needs. The company's primary therapeutic area of interest is autoimmune diseases. Its development pipeline has included proprietary drug candidates for conditions such as Systemic Lupus Erythematosus (SLE).

Recent filings

Filing Released Lang Actions
Report Publication Announcement 2007
Report Publication Announcement Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer submitted to the SEC. It references the 2006 Annual Report of XTL Biopharmaceuticals Ltd. but does not contain the report itself. Instead, it announces the publication and availability of the Annual Report, including where it can be inspected and downloaded. The document length is short (2248 characters), and it primarily serves as a publication announcement rather than the full Annual Report. According to the 'Menu vs Meal' rule, this should be classified as a Report Publication Announcement (RPA).
2007-05-29 English
Regulatory Filings 2007
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by a foreign private issuer, XTL Biopharmaceuticals Ltd., submitted to the SEC. It announces the company's upcoming presentation at a healthcare conference, providing details about the event, the presenter, and the company's business overview. There are no financial statements, detailed financial analysis, or comprehensive report content included. The document is relatively short (3763 characters) and serves as an announcement of an event rather than a full report or detailed financial disclosure. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is also not a certification or insider transaction report. Given these factors, the filing best fits the category of Regulatory Filings (RNS), which is a general category for miscellaneous regulatory announcements that do not fit other specific categories.
2007-05-09 English
Other Report or Announcement
Investor Presentation Classification · 95% confidence The document is a press release announcing that XTL Biopharmaceuticals will present at a healthcare conference. It mentions the date and time of the presentation and provides a webcast link. The content focuses on the upcoming investor presentation and company overview rather than financial results or regulatory filings. The document length is short (2194 characters), and it does not contain financial statements or detailed analysis. Therefore, it fits the category of an Investor Presentation announcement rather than a full report or earnings release.
2007-05-09 Hebrew (modern)
Other Report or Announcement
Report Publication Announcement Classification · 98% confidence The document is a short regulatory filing (1644 characters) submitted to the Israel Securities Authority and the Tel Aviv Stock Exchange. The key section states: "Attached hereto is a report on *XTL presentation at the Acumen Bio Fin Rodman & Renshaw 4th annual Conference*" followed by a filename (*AcumenBioFinFinal_isa.pdf*). This structure indicates that the document itself is an announcement about the publication of a presentation, rather than the full presentation or a comprehensive financial report. According to Rule 2, when a document is short and announces that another report is attached or published, it should be classified as a Report Publication Announcement (RPA). The content explicitly mentions an 'XTL presentation'.
2007-05-09 English
Regulatory Filings 2007
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC. It references a regulatory announcement as an exhibit but does not contain substantive financial data or detailed report content itself. The document length is short (1756 characters), and it primarily serves as a cover or notification filing. According to the rules, such filings that announce or attach reports but do not contain the reports themselves should be classified as Regulatory Filings (RNS).
2007-03-29 English
Regulatory Filings 2007
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by a foreign private issuer, XTL Biopharmaceuticals Ltd., submitted to the SEC. It announces the completion of a Phase I clinical study for a drug candidate, providing detailed information about the study results, pharmacokinetics, and future plans. The document is not a full annual or quarterly report, nor is it an earnings release or a regulatory certification. It is a regulatory announcement of clinical trial results and business updates. Form 6-K filings are typically considered Regulatory Filings (RNS) as they provide miscellaneous updates from foreign private issuers that do not fit into other specific categories. The document length (8350 characters) and content confirm it is a standalone regulatory announcement rather than a full report or presentation.
2007-03-29 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.